GSK plc ADR diskutieren

GSK plc (NYSE: GSK) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating on the stock.

GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.

GSK plc (NYSE: GSK) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.

GSK plc (NYSE: GSK) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating.

GSK plc (NYSE: GSK) was upgraded by analysts at Berenberg Bank to a "strong-buy" rating.

GSK plc (NYSE: GSK) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.

GSK plc (NYSE: GSK) had its price target raised by analysts at Jefferies Financial Group Inc. from $52.50 to $53.00. They now have a "buy" rating on the stock.

GSK plc (NYSE: GSK) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.

GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.

Hey there! I've been keeping an eye on GSK plc ADR, and I gotta say, it's looking pretty interesting right now. With RFK Jr. potentially heading up HHS, we're in for a wild ride in the biotech world. It's like we're about to shake up a snow globe and see where all the flakes land, you know? While this might create some short-term turbulence, I think GSK's solid fundamentals and diverse portfolio could help it weather the storm and even come out stronger. It's like they're a sturdy ship in choppy waters - they might get rocked a bit, but they're built to last. Plus, at the current price, it feels like we're getting a decent deal. What do you think? Could this be a chance to grab a quality pharma stock at a discount before it potentially climbs higher?

GSK PLC Sponsored ADR (NYSE: GSK) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.

GSK (NYSE:GSK) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating.

GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.

GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Barclays PLC.

GSK (GSK) had its "outperform" rating reaffirmed by Royal Bank Of Canada.